FDA — authorised 11 September 1953
- Marketing authorisation holder: STASON PHARMS
- Status: approved
🇺🇸 Purixan in United States
FDA authorised Purixan on 11 September 1953
Marketing authorisations
FDA — authorised 13 February 2004
- Application: ANDA040528
- Marketing authorisation holder: HIKMA
- Local brand name: MERCAPTOPURINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 July 2005
- Application: ANDA040594
- Marketing authorisation holder: MYLAN
- Local brand name: MERCAPTOPURINE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 April 2014
- Application: NDA205919
- Marketing authorisation holder: NOVA LABS LTD
- Local brand name: PURIXAN
- Indication: SUSPENSION — ORAL
- Status: approved
FDA — authorised 26 February 2025
- Application: ANDA216418
- Marketing authorisation holder: HIKMA
- Local brand name: MERCAPTOPURINE
- Indication: SUSPENSION — ORAL
- Status: approved
Purixan in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Purixan approved in United States?
Yes. FDA authorised it on 11 September 1953; FDA authorised it on 13 February 2004; FDA authorised it on 1 July 2005.
Who is the marketing authorisation holder for Purixan in United States?
STASON PHARMS holds the US marketing authorisation.